- Home
- PGNY vs WGS Comparison
PGNY vs WGS Comparison
Compare PGNY & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PGNY
- WGS
- Stock Information
- Founded
- PGNY 2008
- WGS 2017
- Country
- PGNY United States
- WGS United States
- Employees
- PGNY N/A
- WGS N/A
- Industry
- PGNY Misc Health and Biotechnology Services
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- PGNY Health Care
- WGS Technology
- Exchange
- PGNY Nasdaq
- WGS Nasdaq
- Market Cap
- PGNY 1.9B
- WGS 2.0B
- IPO Year
- PGNY 2019
- WGS N/A
- Fundamental
- Price
- PGNY $20.03
- WGS $92.08
- Analyst Decision
- PGNY Buy
- WGS Strong Buy
- Analyst Count
- PGNY 9
- WGS 5
- Target Price
- PGNY $21.83
- WGS $82.60
- AVG Volume (30 Days)
- PGNY 1.9M
- WGS 1.3M
- Earning Date
- PGNY 02-27-2025
- WGS 04-28-2025
- Dividend Yield
- PGNY N/A
- WGS N/A
- EPS Growth
- PGNY N/A
- WGS N/A
- EPS
- PGNY 0.57
- WGS N/A
- Revenue
- PGNY $1,167,221,000.00
- WGS $305,450,000.00
- Revenue This Year
- PGNY $4.52
- WGS $18.58
- Revenue Next Year
- PGNY $12.13
- WGS $17.65
- P/E Ratio
- PGNY $35.18
- WGS N/A
- Revenue Growth
- PGNY 7.22
- WGS 50.79
- 52 Week Low
- PGNY $13.39
- WGS $7.72
- 52 Week High
- PGNY $38.98
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- PGNY 34.22
- WGS 51.27
- Support Level
- PGNY $19.54
- WGS $86.35
- Resistance Level
- PGNY $21.97
- WGS $105.67
- Average True Range (ATR)
- PGNY 1.13
- WGS 9.32
- MACD
- PGNY -0.44
- WGS -1.56
- Stochastic Oscillator
- PGNY 6.85
- WGS 28.12
About PGNY Progyny Inc.
Progyny Inc is a company engaged in specializing in fertility and family building benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of the treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments and active management of the selective network of high-quality provider clinics.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.